The six-month continuing resolution before Congress would cut $1.2 billion from the Pentagon's health research into deadly ...

Rwanda is set to become home to Africa’s first manufacturing plant for eye care products and monoclonal antibodies targeting cancer, with completion expected by 2026, according to Dr. Menghis Bairu, ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

Mr Kim said European payers have waited until both drugs are on the market before launching tenders, in order to drive a hard bargain on the price. Roche has had time to defend Herceptin against ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...